Shares of RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company engaged in the discovery, development and commercialization of innovative therapies based on its proprietary, next-generation RNAi platform, surged in trading today.
RXII shares ended the day 32.67% higher at $0.20 on above average volume of 1.43 million.
RXi Pharmaceuticals recently announced the successful initiation of its first ever clinical study with an RNAi compound, RXI-109, using its proprietary self-delivering RNAi technology.
Pamela Pavco, Chief Development Officer of RXi Pharmaceuticals, said that this is an exciting time for RXi Pharmaceuticals and for RNAi technology in general. Pavco said that after an intense period of preparation, RXII is happy to announce the achievement of a major milestone. Pavco added that RXII believes RXI-109 will provide a highly selective and efficacious solution to an important unmet medical need.
Recent Comments